SSP issued for Haloperidol: Urgent actions required by pharmacy teams

SSP issued for Haloperidol: Urgent actions required by pharmacy teams

December 22, 2019

In response to significant ongoing disruption to the supply of Haloperidol 500 microgram capsules (Serenace®), a Serious Shortage Protocol (SSP) has been issued by the Department of Health and Social Care (DHSC) on Monday 23 December 2019. Developed by clinicians, SSP04 provides pharmacists with procedures to follow in providing a suitable alternative product, Haloperidol 500 microgram tablets, in response to the serious shortage affecting the capsules.

All community pharmacies will receive an email to their shared NHSmail account informing them of this SSP. Community pharmacy contractors and their teams are asked to read the relevant SSP documents and to implement the protocols with immediate effect on Monday 23 December 2019. PSNC has produced a contractor briefing for this SSP, click here to view it.

SSP04: Haloperidol 500mcg capsules (Serenace®)

The SSPs may be amended or revoked at any time but currently expires on Monday 23 March 2020 – PSNC will update contractors on any changes.

Whilst Haloperidol 500 microgram capsules (Serenace®) is a fairly low volume line, DHSC believes the disruption to supply has reached a level that requires intervention. The protocol, SSP04 has been authorised by the Secretary of State to help manage the supply issues affecting Haloperidol 500 microgram capsules (Serenace®) and to try to ensure that fewer patients need to be referred to their prescriber.

The SSP recommendations

The SSP provides that the tablet formulation of Haloperidol may be supplied against prescriptions for Haloperidol 500 microgram capsules (Serenace®) as follows:

For prescriptions (NHS or private) requesting: Supply permitted under SSP04:
Haloperiol 500 microgram capsules
or
Serenace® 500 microgram capsules
Haloperidol 500 microgram tablets

The pharmacist must exercise their professional judgement to ensure the alternative product is suitable for the patient.

 Support in implementing the SSPs

The following resources have been developed to support pharmacy teams in using these protocols.

PSNC Briefing 062/19: Serious Shortage Protocols (SSPs): SSP04 – Haloperidol 500 microgram capsules (Serenace®)

Serious Shortage Protocols Operational Guidance

Serious Shortage Protocols Questions & Answers

PSNC’s Serious Shortage Protocols (SSPs) Endorsing Factsheet

PSNC Briefing 023/19: Serious Shortage Protocols – A guide for community pharmacy teams

Background information on SSPs

Further information on what SSPs are and when they may be used is available via the links below.

Serious Shortage Protocols (SSPs) on-demand webinar

Serious Shortage Protocols (SSPs) webpage



Posted in: , , ,


More Latest News >

Wuhan Novel Coronavirus

The Medicines & Healthcare products Regulatory Agency (MHRA) has via its Central Alerting System (CAS) published an alert regarding the...